Navigation Links
Studies Show Pterostilbene Shows Promise for Anti-Aging and Maintaining Healthy Brain

Houston, TX (PRWEB) January 09, 2014

With 1 in 3 seniors dying with Alzheimer’s or another dementia (source), scientists have long been fighting to find a way to preserve brain health as we age. Now, hope comes from a little-known compound found in blueberries called pterostilbene. In clinical studies, pterostilbene has shown promise as a treatment in the protection against age-related diseases, including Alzheimer’s disease.
In the September 2012 study published first in Neurobiology of Aging, researchers looked at mice that were genetically developed as a model of age-related cognitive decline. The mice were give two different compounds containing pterostilbene and resveratrol. The study found that pterostilbene was the most effective at positively affecting brain function. Now, researchers see hope that pterostilbene could offer the same brain-boosting benefits in humans.
The researchers said, “While it is yet to be determined whether the cognitive improvements induced by pterostilbene in the SAMP8 model can be applied to humans, recent reports demonstrate that fruits containing pterostilbene such as blueberries ameliorate cognitive function in aged humans.”

With so many positive cognitive enhancement benefits associated with pterostilbene, it’s no wonder many people are searching for ways to add more of this potent compound to their diet. It was even named one of the best nootropics by A new memory enhancement supplement, Biohack Pure, features pterostilbene as a key ingredient.

“Based on all the research we’ve seen, pterostilbene is a highly effective antioxidant that fights free radicals and plays a key role in cognitive enhancement,” said Jonathan Weisman, president at Biohack Nutrition, makers of Biohack Pure. “We’re really excited for the potential of this berry compound at helping preserve brain health and preventing cognitive decline.”
For more information, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
4. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
5. EMD Millipore Partners with Charles River Laboratories for Improved Viral Clearance Studies
6. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
7. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
8. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
9. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
10. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
11. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) ... research organisation (CRO) market. The trend of outsourcing ... lower margins but higher volume share for the ... and scale, however, margins in the CRO industry ... (CRO) Market ( ), finds that ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
Breaking Biology News(10 mins):